Cargando…
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. However, this drug combination yields only a modest o...
Autores principales: | Prasopporn, Sunisa, Suppramote, Orawan, Ponvilawan, Ben, Jamyuang, Chanette, Chanthercrob, Jantappapa, Chaiboonchoe, Amphun, More-Krong, Pimkanya, Kongsri, Kamonchanok, Suntiparpluacha, Monthira, Chanwat, Rawisak, Korphaisarn, Krittiya, Okada, Seiji, Sampattavanich, Somponnat, Jirawatnotai, Siwanon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748615/ https://www.ncbi.nlm.nih.gov/pubmed/36531039 http://dx.doi.org/10.3389/fonc.2022.1021632 |
Ejemplares similares
-
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2023) -
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022) -
Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors
por: Suntiparpluacha, Monthira, et al.
Publicado: (2023) -
The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
por: Tanjak, Pariyada, et al.
Publicado: (2023) -
BAIAP2L1 enables cancer cell migration and facilitates phospho‐Cofilin asymmetry localization in the border cells
por: Pipatpanyanugoon, Nut, et al.
Publicado: (2021)